-+ 0.00%
-+ 0.00%
-+ 0.00%

Arrowhead Pharmaceuticals posts ESC 2026 investor presentation on SHASTA-3 and SHASTA-4 results

PUBT·08/31/2026 13:18:07
Listen to the news
Arrowhead Pharmaceuticals posts ESC 2026 investor presentation on SHASTA-3 and SHASTA-4 results
  • Arrowhead released an investor webinar slide deck covering 12-month results from the phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran.
  • Presentation highlighted ~80% triglyceride reductions across severe hypertriglyceridemia, with more than 90% of patients below acute pancreatitis risk thresholds.
  • Cumulative acute pancreatitis events fell 78%, including a 100% reduction in the highest-risk subgroup with triglycerides above 880 mg/dL.
  • Safety profile described as favorable, with overall treatment-emergent adverse events similar between plozasiran and placebo.
  • Slides also referenced a prior 2025 commercial launch of REDEMPLO for familial chylomicronemia syndrome across major markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.